FDAnews
www.fdanews.com/articles/170645-ogd-head-kathleen-uhl-steps-down-for-medical-leave

OGD Head Kathleen Uhl Steps Down for Medical Leave

April 3, 2015

FDA Office of Generic Drugs Director Kathleen “Cook” Uhl is stepping down for several months to undergo treatment for colorectal cancer. She will be replaced in the interim by John Peters, head of OGD’s Office of Bioequivalence.

The move sets off a series of musical chairs within OGD, with acting bioequivalence deputy director Dale Conner filling in for Peters and Trueman Sharpe shifting from his position as a medical officer in the clinical review division to second in command of the BE office.

Uhl began her leave on March 30. The agency gave no timetable for her return.

Uhl took the reins of OGD on an interim basis in March 2013 and was named permanent director in January. Her 17-year FDA career includes overseeing OGD’s reorganization and the implementation of the 2012 Generic Drug User Fee Amendments. — Bryan Koenig